Kayode Ogungbenro

Search results

• 2024

  Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis

  Hansel, J., Mannan, F., Robey, R., Kumarendran, M., Bladon, S., Mathioudakis, A., Ogungbenro, K., Dark, P. & Felton, T., 26 Feb 2024, In: JAC-Antimicrobial Resistance. 6, 1, dlae030.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lactam 100%
  • Pharmacokinetics 100%
  • Antiinfective Agent 100%
  • Biological Marker 50%
  • Sepsis 25%

• Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

  Ling, S. F., Ogungbenro, K., Darwich, A. S., Ariff, A. B. M., Nair, N., Bluett, J., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Barton, A. & Plant, D., 23 May 2024, In: Pharmaceutics. 16, 6, 702.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pharmacokinetics 100%
  • Rheumatoid Arthritis 100%
  • Biosimilar Agent 100%
  • Etanercept 100%
  • Adalimumab 100%
• 2023

  A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models

  Yau, E., Gertz, M., Ogungbenro, K., Aarons, L. & Olivares-Morales, A., 1 Mar 2023, In: CPT: Pharmacometrics and Systems Pharmacology. 12, 3, p. 346-359 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Basmisanil 100%

• Development of a sensitive biochemical assay for the detection of tofacitinib adherence

  Church, S., Hyrich, K. L., Ogungbenro, K., Unwin, R. D., Barton, A. & Bluett, J., 6 Apr 2023, In: Analytical Methods. 15, 14, p. 1797-1801 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tofacitinib 100%
  • Rheumatoid Arthritis 42%
  • High Performance Liquid Chromatography 14%
  • Inflammatory Disease 14%
  • Janus Kinase Inhibitor 14%

• Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children

  Cleary, Y., Kletzl, H., Grimsey, P., Heinig, K., Ogungbenro, K., Silber Baumann, H. E., Frey, N., Aarons, L., Galetin, A. & Gertz, M., 1 Jun 2023, In: Clinical Pharmacokinetics. 62, 6, p. 891-904 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Survival Motor Neuron Protein 100%

• Exploring the boundaries for in vitro-in vivo extrapolation: Use of Isolated Rat Hepatocytes in Co-culture and Impact of Albumin Binding Properties in the Prediction of Clearance of Various Drug Types

  Francis, L., Ogungbenro, K., De Bruyn, T., Houston, J. B. & Hallifax, D., 1 Nov 2023, In: Drug Metabolism and Disposition. 51, 11, p. 1463-1473 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Plasma Protein Binding 100%
  • Drug Concentration 50%
  • Epileptic Absence 50%
  • Bovine Serum Albumin 50%
  • Synapsin I 50%

• Investigation of simplified physiologically-based pharmacokinetic models in rat and human

  Yau, E., Olivares-Morales, A., Ogungbenro, K., Aarons, L. & Gertz, M., 1 Mar 2023, In: CPT: Pharmacometrics and Systems Pharmacology. 12, 3, p. 333-345 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pharmacokinetics 100%
  • Diazepam 50%
  • Partition Coefficient 16%

• Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway

  Hodson, D., Mistry, H., Guzzetti, S., Davies, M., Staniszewska, A., Farrington, P., Cadogan, E., Yates, J., Aarons, L. & Ogungbenro, K., 27 Nov 2023, In: CPT: Pharmacometrics and Systems Pharmacology. 12, 11, p. 1640-1652 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Programmed Death 1 Ligand 1 100%
  • Neoplasm 50%
  • Olaparib 50%
  • Ataxia Telangiectasia 50%
  • Combination Drug 25%

• PII-059* Mechanistic Population Pharmacokinetic Modeling of Risdiplam for Extrapolation of Exposure and Cyp3a Drug-drug Interaction in Neonates with Spinal Muscular Atrophy

  Cleary, Y., Kletzl, H., Grimsey, P., Heinig, K., Ogungbenro, K., Silber--Baumann, H., Frey, N., Aarons, L., Galetin, A. & Gertz, M., 1 Mar 2023, In: Clinical Pharmacology & Therapeutics. 113, p. S63 1 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation

  Hodson, D., Mistry, H., Yates, J., Farrington, P., Staniszewska, A., Guzzetti, S., Davies, M., Aarons, L. & Ogungbenro, K., 1 Oct 2023, In: The Journal of pharmacology and experimental therapeutics. 387, 1, p. 44-54 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Mouse 100%
  • Immune Checkpoint Inhibitor 100%
  • Neoplasm 100%
  • Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 44%
  • Deoxyribonucleoprotein 22%

• Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats

  Melillo, N., Scotcher, D., Kenna, J. G., Green, C., Hines, C. D. G., Laitinen, I., Hockings, P. D., Ogungbenro, K., Gunwhy, E. R., Sourbron, S., Waterton, J. C., Schuetz, G. & Galetin, A., 10 Mar 2023, In: Pharmaceutics. 15, 3, 25 p., 896.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multidrug Resistance-Associated Protein 2 100%
  • Pioglitazone 100%
  • Bosentan 100%
  • Asunaprevir 57%
• 2022

  Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease

  Takita, H., Scotcher, D., Chu, X., Yee, K. L., Ogungbenro, K. & Galetin, A., 2 Jun 2022, In: Clinical Pharmacology & Therapeutics.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Elimination 100%
  • Biological Marker 100%
  • Coproporphyrin 100%
  • Chronic Kidney Failure 100%
  • Polypeptide 100%
  37 Downloads (Pure)

• Development of a Biochemical Tofacitinib Adherence Assay in Rheumatoid Arthritis: The Oral Adhere Study

  Church, S., Hyrich, K., Ogungbenro, K., Unwin, R., Barton, A. & Bluett, J., Jun 2022, In: Annals of the rheumatic diseases. 81, p. 605-606 2 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Estimation of in Vivo Fmo3 Ontogeny By Mechanistic Population Pharmacokinetic Modeling of Risdiplam in Infants, Children and Adults with Spinal Muscular Atrophy.

  Cleary, Y., Kletzl, H., Grimsey, P., Ogungbenro, K., Aarons, L., Galetin, A. & Gertz, M., Mar 2022, In: Clinical Pharmacology & Therapeutics. 111, p. S70-S70 1 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Evaluation of area under the concentration curve adjusted by the terminal-phase as a metric to reduce the impact of variability in bioequivalence testing

  Lucas, A., Ogungbenro, K., Yang, S., Aarons, L. & Chen, C., Jan 2022, In: British Journal of Clinical Pharmacology. 88, 2, p. 619-627 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Metrics 100%
  • Enhanced Approach 100%
  • Confidence Interval 100%
  • Bioequivalence 100%
  • Bioavailability 16%

• In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition

  Murata, Y., Neuhoff, S., Rostami-Hodjegan, A., Takita, H., Al-Majdoub, Z. M. & Ogungbenro, K., 13 Jan 2022, In: The AAPS journal. 24, 1, 28.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • In Vivo 100%
  • Pharmacokinetics 100%
  • In Vitro 100%
  • Central Nervous System 80%
  • Central Nervous System Drug 66%
• 2021

  Application of Coproporphyrin I Pbpk Model to Evaluate the Impact of Slco1b1 Genotype, Ethnicity, and Sex on Its Oatp1b-mediated Interactions.

  Takita, H., Barnett, S., Zhang, Y., Menochet, K., Shen, H., Ogungbenro, K. & Galetin, A., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S83-S83 1 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine Bias

  Salem, F., Johnson, T., Hodgkinson, A., Ogungbenro, K. & Rostami-Hodjegan, A., Feb 2021, In: Journal of Clinical Pharmacology. 61, 2, p. 159-171 13 p.

  Research output: Contribution to journal › Article › peer-review

• Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients

  Lombard, A., Mistry, H., Aarons, L. & Ogungbenro, K., 1 Apr 2021, In: British Journal of Clinical Pharmacology. 87, 4, p. 2053-2063 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Chemotherapy 100%
  • Docetaxel 100%
  • Neutropenia 100%
  • Non Small Cell Lung Cancer 100%
  • Overall Survival 50%

• Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study

  Lang, J., Vincent, L., Chenel, M., Ogungbenro, K. & Galetin, A., Jun 2021, In: Clinical Pharmacology & Therapeutics. 109, 6, p. 1618-1630 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Drug-Drug Interaction 100%
  • Pharmacodynamic Modeling 100%
  • CYP3A4 100%
  • Pharmacokinetics 100%
  • Ivabradine 100%
  249 Downloads (Pure)

• Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

  Lombard, A., Mistry, H., Chapman, S. C., Gueorguieva, I., Aarons, L. & Ogungbenro, K., 1 Jun 2021, In: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 161, p. 1-8 8 p., 105781.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Cisplatin 100%
  • Cancer Inhibition 100%
  • Pemetrexed 100%
  • Tumor Growth 100%
  • Pleura Mesothelioma 100%
  52 Downloads (Pure)

• Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

  Fukushima (Cleary), Y., Gertz, M., Grimsey, P., Günther, A., Heinig, K., Ogungbenro, K., Aarons, L., Galetin, A. & Kletzl, H., Dec 2021, In: Clinical Pharmacology & Therapeutics. 110, 6, p. 1547-1557 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Risdiplam 100%
  178 Downloads (Pure)

• Model-based Investigation of Cyp3a Enzyme Inactivation Effect of Risdiplam in Infants, Children, and Adults with Spinal Muscular Atrophy (sma).

  Cleary, Y., Gertz, M., Grimsey, P., Guenther, A., Heinig, K., Ogungbenro, K., Aarons, L., Galetin, A. & Kletzl, H., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S9-S10 2 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Parent-metabolite Physiologically-based Pharmacokinetic/pharmacodynamic (pbpk/pd) Modelling Using Ivabradine, a Cyp3a4 Substrate: Ddi Risk Evaluation in Children.

  Lang, J., Vincent, L., Marylore, C., Ogungbenro, K. & Galetin, A., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S14-S14 1 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability

  Takita, H., Barnett, S., Zhang, Y., Ménochet, K., Shen, H., Ogungbenro, K. & Galetin, A., Feb 2021, In: CPT: Pharmacometrics and Systems Pharmacology. 10, 2, p. 137-147 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Genotyping 100%
  • SLCO1B1 100%
  • Coproporphyrin 100%
  • Drug Interaction 75%
  • Pharmacokinetics 50%

• Physiologically Based Pharmacokinetic Modeling of TransporterMediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats

  Scotcher, D., Melillo, N., Tadimalla, S., Darwich, A., Ziemian, S., Ogungbenro, K., Schutz, G., Sourbron, S. & Galetin, A., 2 Aug 2021, In: Molecular Pharmaceutics. 18, 8, p. 2997-3009 13 p.

  Research output: Contribution to journal › Article › peer-review

• Physiologically-based pharmacokinetic modelling of transporter-mediated hepatic disposition of 1 imaging biomarker gadoxetate in rats

  Scotcher, D., Melillo, N., Tadimalla, S., Darwich, A., Ziemian, S., Ogungbenro, K., Schütz, G., Sourbron, S. P. & Galetin, A., 2021, In: Molecular Pharmaceutics.

  Research output: Contribution to journal › Article › peer-review

• Population and Physiologically-based Pharmacokinetic Modeling of Risdiplam in Infants, Children, and Adults with Spinal Muscular Atrophy (sma).

  Cleary, Y., Kletzl, H., Grimsey, P., Frey, N., Baumann, H., Stillhart, C., Poirier, A., Heinig, K., Fowler, S., Ogungbenro, K., Aarons, L., Galetin, A. & Gertz, M., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S10-S10 1 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Population Pharmacokinetic Modeling and Simulation to Support Qualification of Fatty Acids Tetradecanedioate As Endogenous Probe for Oatp1b1 Transporter.

  Ahmad, A., Takita, H., Ogungbenro, K. & Galetin, A., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S69-S70 2 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters

  Ahmad, A., Ogungbenro, K., Kunze, A., Jacobs, F., Snoeys, J., Rostami‐hodjegan, A. & Galetin, A., 1 May 2021, In: CPT: Pharmacometrics and Systems Pharmacology. 10, 5, p. 467-477

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pharmacokinetic Modeling 100%
  • Biological Marker 100%
  • Pyridoxic Acid 100%
  • Homovanillic Acid 50%
  • Probenecid 37%

• Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions

  Lang, J., Vincent, L., Chenel, M., Ogungbenro, K. & Galetin, A., 1 Oct 2021, In: European Journal of Pharmaceutical Sciences. 165, 14 p., 105932.

  Research output: Contribution to journal › Article › peer-review
• 2020

  Anakinra in COVID-19: important considerations for clinical trials

  King, A., Vail, A., O'Leary, C., Hannan, C., Brough, D., Patel, H., Galea, J., Ogungbenro, K., Wright, M., Pathmanaban, O., Hulme, S. & Allan, S., 1 Jul 2020, In: The Lancet Rheumatology.

  Research output: Contribution to journal › Commentary/debate › peer-review

  Open Access

  File
  27 Downloads (Pure)

• Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution

  Yau, E., Olivares-Morales, A., Gertz, M., Parrott, N., Darwich, A. S., Aarons, L. & Ogungbenro, K., 3 Feb 2020, (E-pub ahead of print) In: The AAPS journal. 22, 2, p. 41

  Research output: Contribution to journal › Article › peer-review

  • Pharmacokinetics 100%
  • Physiologically Based Pharmacokinetic Modelling 33%
  • Phospholipid 33%
  • Extracellular Protein 33%

• Impact of tumour size measurement inter‑operator variability on model‑based drug effect evaluation

  Lombard, A., Mistry, H., Chapman, S. C., Gueoguieva, I., Aarons, L. & Ogungbenro, K., 13 Mar 2020, In: Cancer Chemotherapy and Pharmacology. 9 p., 10.1007/s00280-020-04049-5.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Inhibition 100%
  • Progression 100%
  • Neoplasm 100%
  • Cancer Inhibition 33%
  • Disease Exacerbation 33%

• Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy

  Darwich, A., Polasek, T. M., Aronson, J. K., Ogungbenro, K., Wright, D. F. B., Achour, B., Reny, J.-L., Daali, Y., Eiermann, B., Cook, J., Lesko, L., McLachlan, A. J. & Rostami-Hodjegan, A., 9 Oct 2020, In: Annual Review of Pharmacology and Toxicology. 61

  Research output: Contribution to journal › Review article › peer-review

  • Drug Therapy 100%
  • Accuracy 100%
  • Pharmaceutical Therapy 100%
  • Patient 28%
  • Drug 28%

• Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

  Kontou, A., Sarafidis, K., Begou, O., Gika, H. G., Tsiligiannis, A., Ogungbenro, K., Dokoumetzidis, A., Agakidou, E. & Roilides, E., 24 Mar 2020, (E-pub ahead of print) In: Antimicrobial Agents and Chemotherapy. 64, 4

  Research output: Contribution to journal › Article › peer-review

  • Pharmacokinetics 100%
  • Teicoplanin 100%
  • Creatinine 75%
  • Maintenance Dose 50%
  • Prematurity 50%

• Simultaneous Ivabradine Parent-Metabolite PBPK/PD modelling using a Bayesian estimation method

  Lang, J., Vincent, L., Chenel, M., Ogungbenro, K. & Galetin, A., 18 Aug 2020, (Accepted/In press) In: AAPS Journal.

  Research output: Contribution to journal › Article › peer-review

  • Pharmacodynamic Modeling 100%
  • Pharmacokinetics 100%
  • Ivabradine 100%
  • Pharmacodynamics 66%
  • Drug-Drug Interaction 50%

• The value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: A multi-centre retrospective cohort study

  Berzuini, C., Hannan, C. J., King, A. T., Vail, A., O'Leary, C., Brough, D., Galea, J., Ogungbenro, K., Wright, M., Pathmanaban, O., Hulme, S., Allan, S., Bernardinelli, L. & Patel, H., 2 Aug 2020, (Accepted/In press) In: BMJ Open.

  Research output: Contribution to journal › Article › peer-review

  • Nonlinear 100%
  • Covariate 100%
  • Statistical Method 100%
  • Biomarker Data 100%
  • Cohort Analysis 100%

• Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study

  Berzuini, C., Hannan, C., King, A., Vail, A., O'Leary, C., Brough, D., Galea, J., Ogungbenro, K., Wright, M., Pathmanaban, O., Hulme, S., Allan, S., Bernardinelli, L. & Patel, H. C., 23 Sept 2020, In: BMJ Open. 10, 9, p. e041983

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nonlinear 100%
  • Covariate 100%
  • Statistical Method 100%
  • Biomarker Data 100%
  • Cohort Analysis 100%
• 2019

  An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis

  Ogungbenro, K., Patel, A., Saunders, M., Clark, J. & Duncombe, R., 2019, In: Journal of Pharmacy and Pharmacology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Pharmacokinetics 100%
  • Cetuximab 100%
  30 Downloads (Pure)

• A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents

  Ogungbenro, K., Wagner, J. B., Abdel-Rahman, S., Leeder, J. S. & Galetin, A., 2019, In: European journal of clinical pharmacology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pharmacokinetics 100%
  • Simvastatin 100%
  • Pharmacokinetic Modeling 10%
  • Elimination 10%
  • Hypercholesterolemia 10%

• A Study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months

  Vashisht, R., Bendon, A., Okonkwo, I., Patel, D., Fullwood, C., Ogungbenro, K., Aarons, L. & Darwich, A., 1 Feb 2019, In: Pediatric Anesthesia. 29, 2, p. 161-168 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Levobupivacaine 100%
  • Epidural 100%
  • Glycoprotein 30%
  • Pharmacokinetic Modeling 23%
  • Pharmacokinetics 23%
  301 Downloads (Pure)

• Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared to rosuvastatin and coproporphyrin I

  Barnett, S., Ogungbenro, K., Menochet, K., Shen, H., Humphreys, G. W. & Galetin, A., 1 Jan 2019, In: Journal of Pharmacology and Experimental Therapeutics. 368, 1, p. 125-135 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Biological Marker 100%
  • Coproporphyrin 100%
  • Rosuvastatin 100%
  • Drug-Drug Interaction 57%
  • Rifampicin 42%
  76 Downloads (Pure)

• Development and validation of a methotrexate adherence assay

  Bluett, J., Riba Garcia, I., Verstappen, S., Wendling, T., Ogungbenro, K., Unwin, R. & Barton, A., 5 Jun 2019, In: Annals Of Rheumatic Diseases.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Methotrexate 100%
  • High Performance Liquid Chromatography 30%
  • Pharmacokinetics 30%
  • Rheumatoid Arthritis 20%
  • Cohort Study 10%
• 2018

  A rational approach to dose optimisation of pembrolizumab using cost analysis and pharmacokinetic modelling and simulation.

  Ogungbenro, K., Patel, A., Clark, J. & Lorigan, P., 6 Sept 2018, In: Journal of Clinical Oncology. 34, 15_suppl, p. 9547-9547 1 p.

  Research output: Contribution to journal › Article › peer-review

  • Pharmacokinetic Modeling 100%
  • Pembrolizumab 100%
  • Pharmacokinetics 60%
  • Trough Level 40%
  • Pharmacodynamics 20%

• Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers

  Felton, T., Ogungbenro, K., Boselli, E., Hope, W. & Rodvold, K., 1 May 2018, In: Journal of Antimicrobial Chemotherapy. 73, 5, p. 1340-1347

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Normal Human 100%
  • Piperacillin 100%
  • Lung Infection 22%
  • Antibiotics 11%
  • Pharmacodynamics 11%
  27 Downloads (Pure)

• Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling and simultion

  Barnett, S., Ogungbenro, K., Menochet, K., Shen, H., Humphreys, W. G. & Galetin, A., 2018, In: Clinical Pharmacology & Therapeutics. p. 1-26

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Drug-Drug Interaction 100%
  • Pharmacokinetic Modeling 100%
  • Biological Marker 100%
  • Coproporphyrin 100%
  • Rifampicin 46%
  7 Downloads (Pure)
• 2017

  Advanced methods for dose and regimen finding during drug development: Summary of the EMA /EFPIA workshop on dose finding (London 4-5 December 2014)

  Musuamba, F. T., Manolis, E., Holford, N., Cheung, S. Y. A., Friberg, L., Ogungbenro, K., Posch, M., Yates, J., Berry, S., Thomas, N., Corriol-Rohou, S., Bornkamp, B., Bretz, F., Hooker, A. C., Van Der Graaf, P. H., Standing, J., Pittaway-Hay, J., Cole, S., Gigante, V. & Karlsson, K. & 8 others, Dumortier, T., Benda, N., Serone, F., Das, S., Brochot, A., Falk, E., Hemmings, R. & Skottheim Rusten, I., 19 Jul 2017, In: Clinical Pharmacology & Therapeutics. 6, 7

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tree 100%
  • Pharmacometrics 100%

• Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction

  Satia, I., Tsamandouras, N., Holt, K., Badri, H., Woodhead, M., Ogungbenro, K., Felton, T. W., O'Byrne, P. M., Fowler, S. J. & Smith, J. A., Mar 2017, In: The Journal of allergy and clinical immunology. 139, 3, p. 771-779.e10

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Asthma 100%
  • Capsaicin-Induced Coughing 100%
  • Coughing 71%
  • Normal Human 57%
  • ED50 57%

• Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identification

  Martin, E., Yates, J. W. T., Ogungbenro, K. & Aarons, L., 5 Sept 2017, In: Journal of Pharmacy and Pharmacology. p. 1-9

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Glucose Test 100%
  • Glucose Tolerance Test 100%
  • Intravenous Glucose Tolerance Test 100%
  • Diabetes Mellitus 100%
  • Insulin Sensitivity 50%